Minimal Residual Disease Testing Trend 2026

Minimal residual disease testing detects tiny numbers of cancer cells remaining after treatment, often below microscopy limits. Using methods like flow cytometry or PCR, it helps doctors assess response, predict relapse risk, and guide therapy in leukemias, lymphomas, and myeloma. This sensitive monitoring supports personalized care and may improve long-term outcomes for patients.